Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2013 1
2014 3
2015 3
2016 3
2017 1
2018 7
2019 2
2020 5
2021 4
2022 3
2023 2
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Landscape of driver mutations and their clinical effects on Down syndrome-related myeloid neoplasms.
Sato T, Yoshida K, Toki T, Kanezaki R, Terui K, Saiki R, Ojima M, Ochi Y, Mizuno S, Yoshihara M, Uechi T, Kenmochi N, Tanaka S, Matsubayashi J, Kisai K, Kudo K, Yuzawa K, Takahashi Y, Tanaka T, Yamamoto Y, Kobayashi A, Kamio T, Sasaki S, Shiraishi Y, Chiba K, Tanaka H, Muramatsu H, Hama A, Hasegawa D, Sato A, Koh K, Karakawa S, Kobayashi M, Hara J, Taneyama Y, Imai C, Hasegawa D, Fujita N, Yoshitomi M, Iwamoto S, Yamato G, Saida S, Kiyokawa N, Deguchi T, Ito M, Matsuo H, Adachi S Prof, Hayashi Y, Taga T, Moriya Saito A, Horibe K, Watanabe K, Tomizawa D, Miyano S, Takahashi S, Ogawa S, Ito E. Sato T, et al. Among authors: moriya saito a. Blood. 2024 Mar 21:blood.2023022247. doi: 10.1182/blood.2023022247. Online ahead of print. Blood. 2024. PMID: 38513239
High-dose cytarabine induction therapy and flow cytometric measurable residual disease monitoring for children with acute myeloid leukemia.
Tomizawa D, Matsubayashi J, Iwamoto S, Hiramatsu H, Hasegawa D, Moritake H, Hasegawa D, Terui K, Hama A, Tsujimoto SI, Kiyokawa N, Miyachi H, Deguchi T, Hashii Y, Iijima-Yamashita Y, Taki T, Noguchi Y, Koike K, Koh K, Yuza Y, Moriya Saito A, Horibe K, Taga T, Tanaka S, Adachi S. Tomizawa D, et al. Among authors: moriya saito a. Leukemia. 2024 Jan;38(1):202-206. doi: 10.1038/s41375-023-02075-9. Epub 2023 Nov 6. Leukemia. 2024. PMID: 37926712 No abstract available.
The incidence of symptomatic osteonecrosis is similar between Japanese children and children in Western countries with acute lymphoblastic leukaemia treated with a Berlin-Frankfurt-Münster (BFM)95-based protocol.
Moriya K, Imamura T, Katayama S, Kaino A, Okamoto K, Yokoyama N, Uemura S, Kitazawa H, Sekimizu M, Hiramatsu H, Usami I, Ishida H, Hasegawa D, Hama A, Moriya-Saito A, Sato A, Sasahara Y, Suenobu S, Horibe K, Hara J; Japan Association of Childhood Leukemia Study Group (JACLS). Moriya K, et al. Among authors: moriya saito a. Br J Haematol. 2022 Mar;196(5):1257-1261. doi: 10.1111/bjh.17988. Epub 2021 Dec 8. Br J Haematol. 2022. PMID: 34879431
Hematopoietic stem cell transplantation for infants with high-risk KMT2A gene-rearranged acute lymphoblastic leukemia.
Takachi T, Watanabe T, Miyamura T, Moriya Saito A, Deguchi T, Hori T, Yamada T, Ohmori S, Haba M, Aoki Y, Ishimaru S, Sasaki S, Ohshima J, Iguchi A, Takahashi Y, Hyakuna N, Manabe A, Horibe K, Ishii E, Koh K, Tomizawa D. Takachi T, et al. Among authors: moriya saito a. Blood Adv. 2021 Oct 12;5(19):3891-3899. doi: 10.1182/bloodadvances.2020004157. Blood Adv. 2021. PMID: 34500465 Free PMC article.
Prognostic factors of Erdheim-Chester disease: a nationwide survey in Japan.
Toya T, Ogura M, Toyama K, Yoshimi A, Shinozaki-Ushiku A, Honda A, Honda K, Hosoya N, Murakami Y, Kawashima H, Nannya Y, Arai S, Nakamura F, Shinoda Y, Nangaku M, Miyagawa K, Fukayama M, Moriya-Saito A, Katayama I, Ogura T, Kurokawa M. Toya T, et al. Among authors: moriya saito a. Haematologica. 2018 Nov;103(11):1815-1824. doi: 10.3324/haematol.2018.190728. Epub 2018 Jul 5. Haematologica. 2018. PMID: 29976744 Free PMC article. Clinical Trial.
A phase III clinical trial evaluating efficacy and safety of minimal residual disease-based risk stratification for children with acute myeloid leukemia, incorporating a randomized study of gemtuzumab ozogamicin in combination with post-induction chemotherapy for non-low-risk patients (JPLSG-AML-20).
Tomizawa D, Tsujimoto SI, Tanaka S, Matsubayashi J, Aoki T, Iwamoto S, Hasegawa D, Nagai K, Nakashima K, Kawaguchi K, Deguchi T, Kiyokawa N, Ohki K, Hiramatsu H, Shiba N, Terui K, Saito AM, Kato M, Taga T, Koshinaga T, Adachi S. Tomizawa D, et al. Among authors: saito am. Jpn J Clin Oncol. 2022 Oct 6;52(10):1225-1231. doi: 10.1093/jjco/hyac105. Jpn J Clin Oncol. 2022. PMID: 35809896 Clinical Trial.
Characteristics of genetic alterations of peripheral T-cell lymphoma in childhood including identification of novel fusion genes: the Japan Children's Cancer Group (JCCG).
Ohki K, Kiyokawa N, Watanabe S, Iwafuchi H, Nakazawa A, Ishiwata K, Ogata-Kawata H, Nakabayashi K, Okamura K, Tanaka F, Fukano R, Hata K, Mori T, Moriya Saito A, Hayashi Y, Taga T, Sekimizu M, Kobayashi R; Japan Children’s Cancer Study Group (JCCG). Ohki K, et al. Among authors: moriya saito a. Br J Haematol. 2021 Aug;194(4):718-729. doi: 10.1111/bjh.17639. Epub 2021 Jul 13. Br J Haematol. 2021. PMID: 34258755
JACLS ALL-02 SR protocol reduced-intensity chemotherapy produces excellent outcomes in patients with low-risk childhood acute lymphoblastic leukemia.
Takahashi Y, Ishida H, Imamura T, Tamefusa K, Suenobu S, Usami I, Yumura-Yagi K, Hasegawa D, Nishimura S, Suzuki N, Hashii Y, Deguchi T, Moriya-Saito A, Kosaka Y, Kato K, Kobayashi R, Kawasaki H, Hori H, Sato A, Kudo T, Nakahata T, Oda M, Hara J, Horibe K. Takahashi Y, et al. Among authors: moriya saito a. Int J Hematol. 2022 Jun;115(6):890-897. doi: 10.1007/s12185-022-03315-x. Epub 2022 Mar 8. Int J Hematol. 2022. PMID: 35258855
Risk-adjusted therapy for pediatric non-T cell ALL improves outcomes for standard risk patients: results of JACLS ALL-02.
Hasegawa D, Imamura T, Yumura-Yagi K, Takahashi Y, Usami I, Suenobu SI, Nishimura S, Suzuki N, Hashii Y, Deguchi T, Moriya-Saito A, Kato K, Kosaka Y, Hirayama M, Iguchi A, Kawasaki H, Hori H, Sato A, Kudoh T, Nakahata T, Oda M, Hara J, Horibe K; Japan Association of Childhood Leukemia Study Group (JACLS). Hasegawa D, et al. Among authors: moriya saito a. Blood Cancer J. 2020 Feb 27;10(2):23. doi: 10.1038/s41408-020-0287-4. Blood Cancer J. 2020. PMID: 32107374 Free PMC article. Clinical Trial.
31 results